Literature DB >> 2562847

Inhibition of cellular DNA synthesis by reovirus occurs through a receptor-linked signaling pathway that is mimicked by antiidiotypic, antireceptor antibody.

G N Gaulton1, M I Greene.   

Abstract

Mammalian reovirus type 3 binds to a 67-kD surface glycoprotein on the membrane of neuronal cells. This interaction initiates the infective reovirus cycle. The physiological function of this virus receptor is not known, however, initial studies illustrate a striking structural and antigenic homology to the beta adrenergic receptor family. The earliest known pathologic effect of reovirus type 3 is an inhibition of host cell DNA synthesis within 8-10 h after virus attachment. The studies reported here demonstrate that binding and aggregation of reovirus receptor molecules provides the signal for this inhibitory process. Inhibition of DNA synthesis in the neuroblastoma cell line B104.G4 was unaffected by using replication-defective virus or when lysosomal processing of normal virus was blocked. Inhibition was mimicked by an antiidiotypic, antireceptor mAb. Inhibition was not observed when monovalent mAb fragments were bound to receptors, but was reconstituted when these fragments were aggregated by the addition of anti-Ig. The signal for the inhibitory effect was generated within the first 60 min after mAb binding. These observations demonstrate that reovirus and antiidiotypic pathogenicity can result from the perturbation of membrane proteins that may perform normal physiological functions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562847      PMCID: PMC2189184          DOI: 10.1084/jem.169.1.197

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

1.  MACROMOLECULAR SYNTHESIS IN REOVIRUS-INFECTED L CELLS.

Authors:  P J GOMATOS; I TAMM
Journal:  Biochim Biophys Acta       Date:  1963-08-20

2.  Cellular DNA replication in infections with cytocidal RNA viruses.

Authors:  R Hand; W D Ensminger; I Tamm
Journal:  Virology       Date:  1971-06       Impact factor: 3.616

3.  Standardization of the chloramine-T method of protein iodination.

Authors:  R Hunter
Journal:  Proc Soc Exp Biol Med       Date:  1970-03

4.  The step in cellular DNA synthesis blocked by reovirus infection.

Authors:  W D Ensminger; I Tamm
Journal:  Virology       Date:  1969-12       Impact factor: 3.616

5.  Evidence that the sigma 1 protein of reovirus serotype 3 is a multimer.

Authors:  R Bassel-Duby; M L Nibert; C J Homcy; B N Fields; D G Sawutz
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Intracellular digestion of reovirus particles requires a low pH and is an essential step in the viral infectious cycle.

Authors:  L J Sturzenbecker; M Nibert; D Furlong; B N Fields
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Genetic studies on the mechanism of chemical and physical inactivation of reovirus.

Authors:  D Drayna; B N Fields
Journal:  J Gen Virol       Date:  1982-11       Impact factor: 3.891

8.  Reovirus: effect of noninfective viral components on cellular deoxyribonucleic acid synthesis.

Authors:  R Hand; I Tamm
Journal:  J Virol       Date:  1973-02       Impact factor: 5.103

9.  Does the beta-adrenergic receptor function as a reovirus receptor?

Authors:  A H Choi; P W Lee
Journal:  Virology       Date:  1988-03       Impact factor: 3.616

10.  Inhibition of synchronized cellular deoxyribonucleic acid synthesis during Newcastle disease virus, mengovirus, or reovirus infection.

Authors:  W D Ensminger; I Tamm
Journal:  J Virol       Date:  1970-06       Impact factor: 5.103

View more
  12 in total

1.  Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes.

Authors:  J A Cohen; W V Williams; D B Weiner; H M Geller; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

2.  Anti-reovirus receptor antibody accelerates expression of the optic nerve oligodendrocyte developmental program.

Authors:  J A Cohen; W V Williams; H M Geller; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

3.  Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis.

Authors:  S M Oberhaus; R L Smith; G H Clayton; T S Dermody; K L Tyler
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Development of biologically active peptides based on antibody structure.

Authors:  W V Williams; D A Moss; T Kieber-Emmons; J A Cohen; J N Myers; D B Weiner; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Linkage between reovirus-induced apoptosis and inhibition of cellular DNA synthesis: role of the S1 and M2 genes.

Authors:  K L Tyler; M K Squier; A L Brown; B Pike; D Willis; S M Oberhaus; T S Dermody; J J Cohen
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Differences in the capacity of reovirus strains to induce apoptosis are determined by the viral attachment protein sigma 1.

Authors:  K L Tyler; M K Squier; S E Rodgers; B E Schneider; S M Oberhaus; T A Grdina; J J Cohen; T S Dermody
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 7.  Structure-based design of immunologically active therapeutic peptides.

Authors:  R Murali; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

8.  Enhancement of hepatitis B virus infection by noninfectious subviral particles.

Authors:  M Bruns; S Miska; S Chassot; H Will
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Reovirus type 3 binds to antagonist domains of the beta-adrenergic receptor.

Authors:  S T Donta; J D Shanley
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

10.  Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors.

Authors:  R L Debiasi; M K Squier; B Pike; M Wynes; T S Dermody; J J Cohen; K L Tyler
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.